Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack

This study has been terminated.
Information provided by:
Arginox Pharmaceuticals Identifier:
First received: June 1, 2005
Last updated: August 2, 2006
Last verified: May 2005
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: January 2007
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by Identifier (NCT Number):